MGRXNasdaqServices-Misc Health & Allied Services, NECUS GAAP · USD

Mangoceuticals, Inc

Mangoceuticals, Inc. operates a telemedicine and e-commerce-style healthcare platform focused on men’s wellness. Through MangoRx.com, it connects consumers with licensed healthcare professionals and markets prescription-based products for erectile dysfunction, hair loss, hormone support, and weight management, including compounded products and the FDA-approved PRIME testosterone therapy offering.

Kysy yhtiöstä
Liikevaihto0,5milj. USD
−26,0 %v/v
Liikevoitto (EBIT)−18,0milj. USD
−126,2 %v/v
EBIT-marginaali−3 954,3%
−2 659,9 %-yks.v/v
Nettotulos−20,6milj. USD
−137,1 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2022–2025

−20−15−10−505milj. USD2022: 0,01 milj. USD2022: EBIT −2,0 milj. USD20222023: 0,73 milj. USD2023: EBIT −9,2 milj. USD20232024: 0,62 milj. USD2024: EBIT −8,0 milj. USD20242025: 0,46 milj. USD2025: EBIT −18 milj. USD20250,46−18
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Mangoceuticals, Inc

Liiketoiminta

Osuus liikevaihdosta
Compounded men’s wellness products70 %

Custom-compounded prescription products for ED, hair loss, hormone support, and weight loss.

FDA-approved prescription therapy20 %

PRIME by MangoRx, powered by Kyzatrex®, an oral testosterone replacement therapy.

Telemedicine platform services10 %

Online access to licensed healthcare professionals and prescription fulfillment workflow.

Asiakkaat

The company sells primarily to adult men seeking discreet, online access to prescription wellness treatments. Its customers are typically patients looking for convenience, privacy, and physician-directed treatment for conditions such as erectile dysfunction, hair loss, low testosterone, and weight management. The platform also depends on prescribers and pharmacy fulfillment partners to convert demand into completed orders.

Men seeking ED treatment

Buy Mango ED products for discreet, prescription-based erectile dysfunction care.

Men with hair-loss concerns

Buy Grow-branded products to address hair-loss treatment needs through telemedicine.

Men with low testosterone or hormone issues

Buy Mojo products or PRIME for testosterone-related therapy and symptom management.

Weight-management patients

Buy Slim products for prescription-based weight-loss support.

Telehealth users

Use the platform to connect with licensed healthcare professionals and obtain prescriptions.

Strategia

Management is focused on aggressive customer acquisition through marketing, platform enhancements, and expansion of its men’s wellness product set. The company also wants to grow organically and through acquisitions in technology, health, and wellness, but execution depends on continued access to capital. Its strategy is built around scaling a digital healthcare brand while broadening the product mix and fulfillment capabilities.

Customer acquisition through marketingLyhyt aikaväli

The model depends on generating online demand for prescription products.

Platform and product expansionKeskipitkä aikaväli

Broader offerings can increase repeat usage and cross-sell across men’s wellness categories.

Acquisition-led growthKeskipitkä aikaväli

Acquisitions could add products, technology, or distribution, but require funding and integration.

Maantiede

Mangoceuticals is headquartered in Dallas, Texas and appears to operate primarily in the United States. Its business is tied to U.S. telemedicine, pharmacy fulfillment, and FDA/regulatory requirements, so domestic healthcare rules are a central operating constraint. The company has not disclosed a meaningful country-by-country revenue split in the provided excerpts.

Riskit

The company is highly exposed to FDA, telemedicine, and compounding-pharmacy regulation because its products are prescription-based and sold online. It also faces financing risk, since operations and growth plans depend on external capital and management has indicated that future funding could be dilutive. Product concentration, related-party fulfillment, and the replicability of compounded formulas add competitive and execution risk.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Capital shortage and dilution1Regulatory delay or restriction2Related-party fulfillment dependence3
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Capital shortage and dilutionVaikutus: KorkeaTodennäköisyys: Korkea

    The company states it may need additional debt or equity financing to fund operations and growth.

    KohdistuuWorking capitalMarketingAcquisitionsContinued operations
  2. Regulatory delay or restrictionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The business sells prescription products online and depends on FDA and state healthcare rules.

    KohdistuuProduct approvalsAdvertising claimsManufacturing inspectionsTelemedicine operations
  3. Related-party fulfillment dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    All compounded products and Prime orders are fulfilled by Epiq Scripts, a related-party pharmacy.

    KohdistuuSupply continuityPricingConflicts of interestOperational control
  4. Competitive replication of productsVaikutus: Keskitaso

    The company notes its compounded formulas are publicly disclosed and can be replicated.

    KohdistuuBrand differentiationPricing powerCustomer retention
Kysy Clarifolta: Mangoceuticals, Inc

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for telemedicine and prescription fulfillment

The company sells online healthcare services and prescription products, so timing of delivery and service completion matters.

Vaikutus: Quarterly revenue and deferred revenue balances

Stock-based compensation

The company issued shares for services and compensation, creating non-cash expense and dilution effects.

Vaikutus: Operating expenses and earnings per share

Goodwill and intangible asset impairment

Management explicitly cites impairment testing as a critical estimate.

Vaikutus: Potential non-cash write-downs

Related-party transactions and licensing agreements

Fulfillment and service arrangements with related parties require careful valuation and disclosure.

Vaikutus: Expense recognition, liabilities, and comparability

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Mannatech, Incorporated

MTEX · Medicinal Chemicals & Botanical Products

Tango Therapeutics, Inc.

TNGX · Pharmaceutical Preparations

Cosmos Health Inc.

COSM · Wholesale-Drugs, Proprietaries & Druggists' Sundries

Evofem Biosciences, Inc.

EVFM · Pharmaceutical Preparations

TherapeuticsMD, Inc.

TXMD · Pharmaceutical Preparations

Monte Rosa Therapeutics, Inc.

GLUE · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026